Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.
Saved in:
| Title: | Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies. |
|---|---|
| Authors: | Izgutdina A; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Rashid T; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Temple WC; Department of Pediatrics, Division of Oncology, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.; Department of Pediatrics, Division of Allergy, Immunology, and Bone Marrow Transplantation, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA., Aminov S; Department of Oncology, Blood Cancer Institute, Albert Einstein College of Medicine, Bronx, New York, USA., Patiño-Escobar B; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Walunj S; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Geng H; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Takamatsu H; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.; Department of Hematology, Kanazawa University, Kanazawa, Japan., Gil-Alós D; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain., Kang AS; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Ramos E; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Chen SY; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Johnson H; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Nix MA; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Naik A; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Li M; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA., Yuan CM; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Wang HW; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Sahu S; Department of Oncology, Blood Cancer Institute, Albert Einstein College of Medicine, Bronx, New York, USA., Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Carpenter C; Arc Institute, Palo Alto, California, USA., Salangsang F; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Phojanakong P; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Serrano JAC; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Tariq I; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Zakraoui O; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Steri V; Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Valeri A; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain., Martinez-Lopez J; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO) Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERONC, Madrid, Spain., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts, USA., Parekh S; Department of Medicine, Division of Hematology and Medical Oncology; Department of Oncological Sciences; and Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Verma A; Department of Oncology, Blood Cancer Institute, Albert Einstein College of Medicine, Bronx, New York, USA., Shah NN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Wiita AP; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA arun.wiita@ucsf.edu.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.; Chan Zuckerberg Biohub, San Francisco, California, USA.; Parker Insitute for Cancer Immunotherapy, San Francisco, California, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Dec 30; Vol. 13 (12). Date of Electronic Publication: 2025 Dec 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
